Results 121 to 130 of about 257,231 (311)
Differential expression of mTOR signalling components in drug resistance in ovarian cancer [PDF]
This article has been made available through the Brunel Open Access Publishing Fund and is available from the specified link - Copyright @ 2010 The International Institute of Anticancer Research.Background/Aim: A limitation to successful cancer ...
Coley, HM +5 more
core
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
Protein restriction (PR) slows Alzheimer's disease (AD) in mice, and other benefits of PR are due to decreased branched‐chain amino acids (BCAAs). We show that restricting any BCAA has benefits, with sex‐ and BCAA‐specific impacts on pathology, molecular signaling, and cognition.
Reji Babygirija +22 more
wiley +1 more source
Rapamycin activates mammalian microautophagy
Autophagy-lysosome proteolysis is classified into macroautophagy (MA), microautophagy (mA) and chaperone-mediated autophagy (CMA). In contrast to MA and CMA, mA have been mainly studied in yeast. In 2011, mammalian mA was identified as a pathway to deliver cytosolic proteins into multivesicular bodies.
Masahiro Sato +6 more
openaire +3 more sources
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong +5 more
wiley +1 more source
AbstractRapamycin (1) is a macrocyclic natural product, established as a potent immunosuppressant and currently of interest to the scientific community as the framework for a series of novel anticancer drugs. Extensive studies have culminated in a new convergent total synthesis of 1, which features a number of group‐derived methodologies and an unusual
Ley, S +22 more
openaire +3 more sources
Emerging evidence suggests that intraneuronal Aβ accumulation represents an early pathogenic event in Alzheimer's disease (AD). Using Drosophila AD model, this study shows that a nonsecreted serine protease Yip7 physically interacts with Aβ. This causes intraneuronal Aβ accumulation but surprisingly reduces the associated neurotoxicity, arguing that ...
Jingyun Su +4 more
wiley +1 more source
The αvβ3‐mediated SPRC@MPDA‐RGD targets broken endothelial cells and controllably releases SPRC. CSE is then activated to produce endogenous H2S, which inhibits ferritinophagy. In brief, H2S inhibits autophagy by activating the PI3K/Akt/mTOR pathway, thereby suppressing the ferroptosis process mediated by NCOA4, and ultimately promoting the ...
Zhiheng Chen +11 more
wiley +1 more source
Inhibition of the Mechanistic Target of Rapamycin (mTOR)–Rapamycin and Beyond [PDF]
Rapamycin is a Food and Drug Administration (FDA)-approved immunosuppressant and anticancer agent discovered in the soil of Easter Island in the early 1970s. Rapamycin is a potent and selective inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, which acts as a central integrator of nutrient signaling pathways.
openaire +2 more sources
Human‐relevant methods are essential for modern chemical safety assessment. This study helps define the capabilities and boundaries of an in vitro testing battery for developmental neurotoxicity by exploring its biological applicability domain. By linking neurodevelopmental disease‐related pathways to key neurodevelopmental processes, the work enhances
Eliska Kuchovska +14 more
wiley +1 more source

